This qualitative analysis uses information from US Food and Drug Administration (FDA) documents obtained through a Freedom of Information Act request to characterize the FDA’s decision-making with respect to the regulation of mifepristone, especially the agency’s rationale for establishing, maintaining, or modifying key components of its regulatory approach over time.
Women's Health
|15th Jan, 2026
|Journal of the American Medical Association
Women's Health
|22nd Dec, 2025
|Journal of the American Medical Association
Women's Health
|11th Dec, 2025
|Journal of the American Medical Association
Women's Health
|2nd Dec, 2025
|Journal of the American Medical Association
Women's Health
|27th Nov, 2025
|Journal of the American Medical Association
Women's Health
|27th Nov, 2025
|Journal of the American Medical Association
Women's Health
|24th Nov, 2025
|Journal of the American Medical Association